|  | 2015 | 2017–2021 | 2022–2026 | 2027–2031 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | Vaccination | Current screening program | Current screening program | New screening program | % increase under new program | Current screening program | New screening program | % increase under new program | Current screening program | New screening program | % increase under new program |
Women screened | With vaccination a | 2,297,161 | 2,429,487 | 1,412,933 | −41.8 % | 2,585,465 | 1,442,095 | −44.2 % | 2,737,383 | 1,498,228 | −45.3 % |
 | No vaccination | 2,300,662 | 2,436,693 | 1,430,693 | −41.3 % | 2,595,623 | 1,468,363 | −43.4 % | 2,750,112 | 1,534,421 | −44.2 % |
HPV tests | With vaccination a | 54,380 | 53,273 | 1,413,004 | 2552.4Â % | 50,653 | 1,442,838 | 2748.5Â % | 47,873 | 1,497,588 | 3028.2Â % |
 | No vaccination | 55,857 | 59,390 | 1,430,105 | 2308.0 % | 63,263 | 1,468,317 | 2221.0 % | 66,699 | 1,532,790 | 2198.1 % |
Cytology | With vaccination a | 2,409,923 | 2,544,000 | 370,206 | −85.4 % | 2,702,457 | 323,456 | −88.0 % | 2,857,249 | 313,008 | −89.0 % |
 | No vaccination | 2,418,505 | 2,561,456 | 412,178 | −83.9 % | 2,727,996 | 391,910 | −85.6 % | 2,889,861 | 408,425 | −85.9 % |
ASC-H/HSIL cytology | With vaccination a | 31,002 | 30,661 | 16,607 | −45.8 % | 30,538 | 14,462 | −52.6 % | 30,671 | 14,100 | −54.0 % |
 | No vaccination | 33,532 | 35,399 | 19,504 | −44.9 % | 37,391 | 18,415 | −50.7 % | 39,406 | 19,307 | −51.0 % |
Colposcopies | With vaccination a | 77,508 | 76,462 | 95,367 | 24.7Â % | 75,740 | 82,677 | 9.2Â % | 75,566 | 78,421 | 3.8Â % |
 | No vaccination | 83,234 | 88,087 | 117,901 | 33.8 % | 93,199 | 116,479 | 25.0 % | 98,136 | 121,557 | 23.9 % |
Treatments | With vaccination a | 20,011 | 19,214 | 17,593 | −8.4 % | 18,432 | 15,572 | −15.5 % | 17,895 | 14,694 | −17.9 % |
 | No vaccination | 21,984 | 23,254 | 21,745 | −6.5 % | 24,572 | 22,375 | −8.9 % | 25,871 | 23,395 | −9.6 % |